Purpose: Niemann-Pick disease type C (NP-C) is an autosomal recessive lipid storage disease manifested by an impairment in cellular cholesterol homeostasis. The clinical phenotype of NP-C is extremely variable, ranging from an acute neonatal form to an adult late-onset presentation. To facilitate phenotype-genotype studies, we have analyzed multiple Israeli NP-C families. Methods: The severity of the disease was assessed by the age at onset, hepatic involvement, neurological deterioration, and cholesterol esterification studies. Screening of the entire NPC1 coding sequence allowed for molecular characterization and identification of disease causing mutations.
Niemann-Pick disease type C (NP-C) is an autosomal recessive lipid storage disease manifested by an impairment in cellular cholesterol homeostasis (OMIM number 257220). The prevalence has been estimated at 1:150,000 in Europe, yet the incidence in early life is probably underestimated, because of nonspecific presentations and possible under-diagnosis. Acadians in Nova Scotia, individuals of Hispanic descent in Colorado and New Mexico, and a Bedouin group in Israel represent genetic isolates each with a common founder. In the Acadians of Nova Scotia, a milder variant of the disease that has been at first erroneously considered to be a distinct entity termed Niemann Pick disease type D (NPD), proved later by molecular analysis to be allelic to NP-C. 1 The disease is clinically characterized by progressive degeneration of the central nervous system with visceral accumulation of cholesterol and sphingomyelin. The clinical phenotype of NP-C is extremely variable ranging from an acute neonatal form, showing mainly liver involvement and rapid neurologic deterioration, to an adult late-onset presentation, with slowly progressive ataxia and a movement disorder. The late infantile and juvenile forms are considered to be the most common classical presentations with the insidious onset of ataxia, vertical supranuclear gaze palsy, and cognitive impairment in up to 80% of the patients. 1 The underlying cellular defect is a disruption in the sterol trafficking, which leads to accumulation of free cholesterol within the lysosomal and late-endosomal compartment of the cell. The biochemical nature of NP-C became clear following the identification of a natural murine NP-C model presenting with degenerative lipid storage disease. 2 The affected mice had elevated levels of unesterified cholesterol in various tissues. Although a defect in cholesterol esterification was shown in NP-C patients, 3 acyl CoA:cholesterol acyltransferase (ACAT) deficiency was ruled-out. 4 The accumulation of lysosomal unesterified cholesterol was found to be due to reduced release of free cholesterol from lysosomes to other cellular organelles such as plasma membrane and the Golgi apparatus. 5, 6 Hence, the definitive diagnosis of NP-C is based on the demonstration of abnormal cholesterol esterification in skin fibroblasts cultured with LDL-derived tritiated oleate. This assay provides the means for diagnosis of affected individuals, yet it cannot be utilized for the identification of carriers. Attempts to identify a correlation between the clinical phenotype and the severity of the disruption of cellular cholesterol homeostasis have been inconclusive. [7] [8] [9] [10] Although a "variant" biochemical phenotype was described for patients with the adult-onset presentation, no definitive correlation has been observed for the late infantile and juvenile forms.
The NPC1 gene has been cloned following its mapping to the long arm of chromosome 18 using linkage and positional cloning. 11, 12 The NPC1 cDNA sequence predicts a protein of 1,278 amino acids with an estimated molecular mass of 142 kDa. Recently, topological analysis of the NPC1 protein has revealed the existence of 13 transmembrane domains, 7 luminal loops, 6 cytoplasmic loops, and a cytoplasmic tail. 13 To date, more than 100 NPC1 mutations, mostly missense, have been identified throughout the gene, with no apparent hot spots. 14 -16 Most patients with NPC1 mutations are compound heterozygotes with private unique mutations. The two known exceptions are a common I1061T mutation found in the Hispanic population in the upper Rio Grande Valley in the southwestern United States, and in the United Kingdom, and France 15 and the mutation G992W in the Acadian population of Nova Scotia. 17 According to accumulated data so far, NPC1 is associated with approximately 80% of known cases; however, both linkage techniques and cellular complementation studies have shown the existence of genetic heterogeneity, providing proof for the presence of an additional disease-causing gene. 18 Recently, HE1 encoding a ubiquitously expressed lysosomal cholesterol binding protein was identified as a second gene for NP-C. 19 NP-C patients from both complementation groups demonstrate similar clinical and biochemical phenotypes, suggesting that NPC1 and HE1 may interact or function sequentially in a common metabolic pathway.
NP-C is observed in a relatively high frequency in Israel, 20 especially among the Israeli non-Jewish population comprising Muslim Arabs, Bedouins, Druze, and Samaritans subgroups. A relatively high rate of autosomal recessive disorders is observed as a consequence of the high consanguinity rate among these various groups. In this study, we characterized the clinical, biochemical, and molecular features of NP-C in Israel.
PATIENTS AND METHODS

Patients
The analyzed patients were part of a larger group of 13 affected individuals that were referred to the Biochemical Genetics laboratory in the Department of Human Genetics with a tentative clinical diagnosis of NP-C. This study was approved by the Institutional Review Board in accordance with the World Medical Association Declaration of Helsinki. Informed consent was obtained from the participants in the study or from their parents. The laboratory at the Hadassah University Hospital serves as a national referral lab for the diagnosis of lysosomal storage disorders. 
Molecular studies
Total RNA was extracted from fibroblast monolayers using the TRI Reagent᭨ (Molecular Research Center, Inc.) according to manufacturer's instructions. Reverse transcription was performed using AMV Reverse Transcriptase (Promega) and standard protocols. The NPC1 cDNA was amplified in overlapping fragments, checked by agarose gel electrophoresis, and purified with the AGTC Gel Filtration Cartridges (Edge BioSystems) according to manufacturer's instructions. Sequencing reactions were performed with 50 ng of purified PCR product, 10 pmol primer, and 8 L of ABI PRISM᭨ BigDye TM Terminator Cycle Sequencing Kits with AmpliTaq᭨ DNA Polymerase (Applied Biosystems). Automated sequencing was performed on an ABI PRISM᭨ 310 Genetic Analyzer and processed by means of ABIView version 3.0 software. Every mutation was confirmed by sequencing the product of an independent PCR reaction. Restriction digests were performed in those cases where the mutation introduced a new restriction site or alternatively abolished a site present in the wild-type DNA. Base-pair numbers used refer to GenBank accession AF002020. In order to rule out the possibility of polymorphisms, 100 chromosomes obtained from healthy individuals from similar ethnic backgrounds were screened for the presence of these molecular changes.
RESULTS
Clinical features of NP-C patients
We characterized 9 of 13 families that were referred to our department for investigation because of clinical suspicion of NP-C. In 5 of the families, there were more than one affected sibling. In total, we analyzed 19 affected NP-C patients, of which 12 were assayed biochemically. Demographic and clinical characteristics of the 9 index patients are shown in Table 1 . In 8 of 9 families, parents' consanguinity resulted in homozygous individuals. Two of 9 of the families were of Jewish origin, 1 was Christian, and 6 were of Muslim Arab ancestry. Mostly, the patients were investigated because of hepatosplenomegaly (8 of 9), neonatal jaundice (4 of 9), and neurological symptoms that were identified during the first 2 years of life (4 of 9). The various clinical forms ranged from neonatal and infantile to adult presentations (Table 1) . In 4 families, we observed patients with a juvenile onset of symptoms (SB, SG, AM, SL). In 3 of these families (SB, SG, AM), consanguinity at the first cousin level was demonstrated. One previously described patient (AN) had an adult onset NP-C. 21 This patient was investigated at first because of hepatosplenomegaly and mild ataxia. The presence of supranuclear ophthalmoplegia and "sea-blue" histiocytes at bone marrow biopsy led to clinical suspicion of NP-C. The provisional diagnosis of NP-C was based on filipin staining and linkage analysis. An additional affected family (ARZ) was previously described due to the striking phenotypic variation within family members. 22 Three NP-C affected individuals died following several months of progressive hepatic failure, while another child presented with hepatosplenomegaly and no other abnormality to the age of 30 months. Neurologic deterioration developed from that point with progressive mental retardation and severe pneumonitis leading to death at the age of 5 years. Considerable variability in the clinical presentation was also observed in the ABR kinship. In addition to the currently investigated ABR patients, two previously confirmed NP-C cases presenting with hydrops fetalis and hepatomegaly were reported. 23 Esterification assays correlate with the clinical phenotype
The biochemical diagnosis of NP-C in fibroblasts was done using both filipin fluorescence tests (data not shown), and esterification assays. We performed the esterification measurements following 4.5 and 24 hours incubation periods. Two groups were distinctive following 4.5 hours of incubation: one that showed low esterification levels (0.88 Ϯ 0.85 and 2.10 Ϯ 1.96 nmol/mg protein) and corresponded to the severe infantile and the intermediate juvenile clinical phenotypes; and a second group with a "variant" biochemical phenotype that did not differ at large from normal controls (23.40 Ϯ 23.00 as compared with 50.00 Ϯ 32.00 nmol/mg protein). Following 24 hours of incubation, we were able to classify three biochemical phenotypes: a "variant" phenotype appearing in adult-onset patients with no differences in cholesterol esterification values when compared to the control (627 Ϯ 247 and 738 Ϯ 262 nmol/mg protein, respectively); a "severe" biochemical phenotype corresponding to the early infantile phenotype that showed no increase in esterification levels following 24 hours of incubation (26.00 Ϯ 18.20 nmol/mg protein); and an "intermediate" biochemical phenotype that clearly demonstrated a recovery in cholesterol ester production following 24 hours of incubation and was distinguishable from both the "variant" phenotype and the severe infantile biochemical phenotype (Table 2) . Although these results are indicative for possible correlation between the clinical and the biochemical phenotypes, the small number of assayed patients preclude drawing statistically significant conclusions. Table 1 documents the various mutations that were detected in multiple NP-C patients. Of the 13 index patients that were analyzed, we characterized NPC1 mutations in 9 (69%). The mutations were identified in the various clinical phenotypes of NP-C. In order to confirm that these indeed are mutations and not polymorphisms, we have screened a total of 100 chromosomes from 50 independent individuals that belong to similar ethnic groups and found none of these changes among healthy individuals.
We observed both missense and nonsense mutations spread throughout the gene with no apparent clustering. The adultonset phenotype (AN) was homozygous for a missense conversion of an aliphatic valine for alanine. Within the early infantile group (SA, MH, ABR), there were both nonsense and missense homozygotes. The only compound heterozygote belonged to the juvenile group (SL) having both nonsense and missense alleles.
A G992W mutation previously detected in the Nova Scotian genetic isolate 17 was found in two independent Muslim Arab families originating from the northern part of Israel (AM and SG). We examined four affected individuals in these families and found the phenotypic severity to be similar to that previously described in the Nova Scotian patients. 24 
DISCUSSION
In this study, we characterized the clinical, molecular, and biochemical features of Israeli NP-C patients. We show that in our patients NP-C has a striking inter-and intrafamilial phenotypic variability. This variability may result from either genetic or environmental factors.
In accordance with previous observations that showed a high prevalence of the severe infantile neurological form in the Middle East, 8 we observed in four of the nine characterized families a phenotype conforming to the neonatal appearance of jaundice and rapid neurological deterioration.
Cholesterol esterification assays following 4.5 and 24 hours of incubation allowed us to differentiate among three distinct biochemical patterns: (I) an ongoing block of esterification following 4.5 and 24 hours of incubation with LDL-cholesterol, (II) a block in esterification that partially resolved following 24 hours of incubation, and (III) a normal esterification profile following 4.5 and 24 hours that was observed in affected adult-onset patients from the AN family. Following 24 hours of incubation, three distinctive biochemical phenotypes emerged. A previously recorded "variant" phenotype that did not differ from the normal control and two additional biochemical phenotypes that correlated with the clinical findings. In patients with severe infantile course (MH, ABR, SA), we found reduced levels of esterification that did not increase following 24 hours of incubation with LDL and H 3 -oleic acid. In comparison, in patients with a moderate phenotype represented by juvenile onset of clinical symptoms (SB, AM, SG), we observed a severe esterification block following 4.5 hours of incubation, as previously shown, 7, 8 with partial removal of the block following 24 hours of incubation was seen ( Table 2 ). This may point to either residual activity of the NPC1 protein or to contribution of additional proteins participating in cellular sterol trafficking. The attempted correlation between the clinical and the biochemical phenotype is based on 12 assayed affected individuals and, thus, needs validation by adding more patients. This may help in the utilization of the biochemical tests as means for predicting the disease prognosis. Our findings confirm previous reports that focused on the differences in esterification and cholesterol homeostasis between cells obtained from patients with the classical NP-C phenotype as compared with cells obtained from the Nova Scotian milder phenotype. 9, 10 Indeed, two individuals with "moderate" biochemical phenotype (AM, SG) had the same mutation as that described in the Nova Scotian genetic isolate 17, 24 (Table 1) .
In accordance with the high degree of consanguinity among our tested population, we found 8 of the 9 families characterized, to be homozygotes. We identified eight novel mutations and one previously described mutation. Homozygous patients offer an opportunity to study the phenotypic effect of specific molecular changes. Among severely affected patients, we identified one nonsense mutation (3347 del TC) truncating the protein within the 9 th transmembrane domain, and three missense mutations. C63R is positioned in the luminal N-terminus of the NPC1 protein proximal to the first transmembrane domain. R404Q is located to the luminal side of the NPC1 protein between the 2 nd and 3 rd transmembrane domains in a region that is predicted to harbor several potential N-glycosylation sites. G1012D, which is associated with the severe phenotype, is located in the luminal side between the 8 th and 9 th transmembrane domains in the same region as is the A927 V mutation that was identified within the mildly affected phenotype. Of the homozygous mutations causing an intermediate phenotype, N1156S and G992W are located within the luminal portion of the protein between the 10 th and 11 th , and the 8 th and 9 th transmembrane domains, respectively. Thus, based on our study, no obvious correlation between the site of the molecular defect and the clinical phenotype can be determined. Cultured cells were seeded in MEM ϩ 5% LPDS serum for 2 to 4 days after which 100 g of LDL and H 3 -oleic acid were added and cholesteryl ester formation was measured (Ϯ standard deviation).
Of the various NP-C mutations identified within the Israeli families, 7 were found to be private and 2 were common to more than one family. One of the common mutations, R404Q, was identified in several affected individuals originating from a Bedouin isolate in the Southern part of Israel. This mutation is easily detected using an MspI restriction analysis that may be useful for carrier screening. It should be noted that, in the Bedouin society, marriages are often prearranged by parents, and there is a known reluctance for prenatal diagnosis and termination of pregnancies. [25] [26] [27] Thus, by administering proper information and counseling, NP-C genetic screening could be applied within this isolate.
An additional common mutation, G992W, was detected in two distinct nonrelated families that originated from the northern part of Israel. This mutation was previously described as causing the Nova Scotia variant. 24 The clinical and biochemical characteristics of the individuals with the G992W mutation is similar to that previously reported. It remains to be shown whether this mutation occurred twice or results from a common founder.
An important aspect of molecular diagnosis applies to cases with adult onset of symptoms. In these patients, the known biochemical assays do not allow adequate diagnosis and cannot be applied for prenatal diagnosis. 21, 28 Thus, molecular diagnosis of the specific mutation aids both in direct diagnosis of affected individuals and in accurate detection of carriers among this highly consanguineous population.
It is interesting to note that, although three of our affected NP-C individuals originated from villages within a small geographic area, each had a distinct mutation. This finding has been previously described and discussed with regard to other autosomal recessive disorders, mainly Hurler (MIM 252800), 29 primary hyperoxaluria type 1 (PH1 MIM 259900), 30 and metachromatic leukodystrophy (MLD MIM 250100). 31 The finding of multiple recessive mutations in a single gene as the cause for an increased disease frequency may result from selective advantage for heterozygotes, although no evidence for this has been shown. A plausible possibility is that each newly occurring recessive mutation in a distinct homogeneous population could lead to a homozygous affected individual within a small number of generations due to the high rate of consanguinity in families in combination with a large number of offspring.
